FOXO4-DRI is a synthetic peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53 within senescent cells. This disruption leads to the selective apoptosis (programmed cell death) of these harmful cells. By clearing senescent cells, FOXO4-DRI is theorized to reduce chronic inflammation, improve tissue function, and mitigate age-related decline, thereby promoting healthspan.
Verdict
Promising senolytic in animals, but human data is entirely absent.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
High
EVIDENCE GRADE
C
MONTHLY COST
$100 - $500
Protocol
- Experimental protocols in animals involve intermittent subcutaneous injections, often weekly or bi-weekly, over several weeks to induce senescent cell apoptosis.
Flags
- Currently a research chemical, not approved for human therapeutic use.
- No human safety or efficacy data available for healthspan applications.
- Potential for off-target effects and immunogenicity due to peptide nature.
- Long-term risks and optimal dosing in humans are entirely unknown.